Literature DB >> 22025954

The clinical usefulness of nuclear matrix protein-22 in patients with atypical urine cytology.

Jae Sung Ahn1, Hyun-Soo Kim, Sung-Goo Chang, Seung Hyun Jeon.   

Abstract

PURPOSE: Difficulty exists in interpreting the significance of atypical urine cytology. This study was performed to assess the diagnostic utility of nuclear matrix protein-22 (NMP-22) testing when atypical cells are detected during urine cytology.
MATERIALS AND METHODS: Among patients whose urine cytology was reported as atypical between January 2004 and December 2009, a total of 275 who also underwent NMP-22 testing were enrolled in the present study. These patients were further divided into the screening group (143 patients examined as outpatients for hematuria) and the follow-up group (132 patients followed up for previously diagnosed bladder cancer). The sensitivity, specificity, positive and negative predictive values, and accuracy were assessed for atypical cytology alone and in conjunction with NMP-22.
RESULTS: Of the 275 patients exhibiting atypical urine cytology, cancer was confirmed in 85, yielding a positive predictive value of 30.9% (85/275). Of the 96 patients testing positive for NMP-22, 58 were diagnosed with bladder cancer. The positive predictive value in conjunction with NMP-22 was 60.4% (58/96). The sensitivity, specificity, negative predictive value, and accuracy were 68.2% (58/85), 80.0% (152/190), 84.9% (152/179), and 76.2% (210/275), respectively. Testing for NMP-22 in the screening and follow-up groups increased the positive predictive value from 30.0% (43/143) to 64.0% (32/50) and from 31.3% (42/132) to 56.5% (26/46), respectively; there was no significant difference between the screening and follow-up groups (p=0.106).
CONCLUSIONS: When only cases with atypical urine cytology were examined, NMP-22 testing increased the detection rate of bladder cancer regardless of whether the test was used in screening hematuria or in following up patients.

Entities:  

Keywords:  Cytology; Nuclear matrix; Urinary bladder neoplasms

Year:  2011        PMID: 22025954      PMCID: PMC3198232          DOI: 10.4111/kju.2011.52.9.603

Source DB:  PubMed          Journal:  Korean J Urol        ISSN: 2005-6737


  15 in total

1.  Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat.

Authors:  S Sharma; C D Zippe; L Pandrangi; D Nelson; A Agarwal
Journal:  J Urol       Date:  1999-07       Impact factor: 7.450

2.  Analysis of atypical urine cytology in a tertiary care center.

Authors:  Vikram Deshpande; Grace T McKee
Journal:  Cancer       Date:  2005-12-25       Impact factor: 6.860

3.  Screening and monitoring for bladder cancer: refining the use of NMP22.

Authors:  L E Ponsky; S Sharma; L Pandrangi; S Kedia; D Nelson; A Agarwal; C D Zippe
Journal:  J Urol       Date:  2001-07       Impact factor: 7.450

4.  Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?--experience at Kuwait University.

Authors:  K Kapila; E O Kehinde; J T Anim; O A Mojiminiyi; A Vinsu; S S George; M Al-Maghrebi; F Al-Mulla
Journal:  Cytopathology       Date:  2008-07-09       Impact factor: 2.073

5.  Pathologist's role in bladder cancer.

Authors:  G M Farrow
Journal:  Semin Oncol       Date:  1979-06       Impact factor: 4.929

6.  Utility of urine cytology in the workup of asymptomatic microscopic hematuria in low-risk patients.

Authors:  Andrew H Feifer; Jordan Steinberg; Simon Tanguay; Armen G Aprikian; Fadi Brimo; Wassim Kassouf
Journal:  Urology       Date:  2010-02-07       Impact factor: 2.649

7.  Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer.

Authors:  N Miyanaga; H Akaza; S Ishikawa; M Ohtani; R Noguchi; K Kawai; K Koiso; M Kobayashi; A Koyama; T Takahashi
Journal:  Eur Urol       Date:  1997       Impact factor: 20.096

8.  The clinical utility of atypical cytology is significantly increased in both screening and monitoring for bladder cancer when indexed with nuclear matrix protein-22.

Authors:  Rupesh Raina; Geetu Pahlajani; Lee E Ponsky; Ashok Agarwal; Craig D Zippe
Journal:  BJU Int       Date:  2008-08       Impact factor: 5.588

9.  Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder.

Authors:  Pierre I Karakiewicz; Serge Benayoun; Craig Zippe; Gerson Lüdecke; Hans Boman; Marta Sanchez-Carbayo; Roberto Casella; Christine Mian; Martin G Friedrich; Sanaa Eissa; Hideyuki Akaza; Hartwig Huland; Hans Hedelin; Raina Rupesh; Naoto Miyanaga; Arthur I Sagalowsky; Michael J Marberger; Shahrokh F Shariat
Journal:  BJU Int       Date:  2006-03-17       Impact factor: 5.588

10.  How important is urinary cytology in the diagnosis of urological malignancies?

Authors:  Ghulam Nabi; D R Greene; Mary O'Donnell
Journal:  Eur Urol       Date:  2003-06       Impact factor: 20.096

View more
  3 in total

Review 1.  [Urine cytology - update 2013. A systematic review of recent literature].

Authors:  M Böhm; F vom Dorp; M Schostak; O W Hakenberg
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

Review 2.  Urinary Markers for Bladder Cancer Diagnosis and Monitoring.

Authors:  Seung-Hwan Jeong; Ja Hyeon Ku
Journal:  Front Cell Dev Biol       Date:  2022-05-02

Review 3.  Novel non invasive diagnostic strategies in bladder cancer.

Authors:  Anamaria Truta; Tudor Adrian Hodor Popon; George Saraci; Liviu Ghervan; Ioan Victor Pop
Journal:  Clujul Med       Date:  2016-04-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.